Company Overview
Company Type: Public Company
Website: www.entheonbiomedical.com
Number of Employees: 2
Ticker: ENBI (CNSX)
Year Founded: -


Business Description
Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.4
Market Capitalization
1.2
TEV/Total Revenue
1.6x
Total Enterprise Value
0.7
EBIT
(1.0)
Cash & ST Invst.
0.5
P/Diluted EPS Before Extra
3.9x
Net Income
(5.5)
Total Debt
0.0
Price/Tang BV
2.4x
Total Assets
0.6


Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Ko, Timothy 
President, CEO & Director
Kim, Soo-Whan 
Interim Chief Financial Officer
Jahns, Brian E.
Chief Business Officer
Pladson, Kelly 
Corporate Secretary

Key Board Members
Name
Title
Ko, Timothy 
President, CEO & Director
Gondi, Christopher 
Independent Director
Carhart-Harris, Robin L.
Scientific Advisor
Erritzoe, David 
Scientific Advisor
Greenshaw, Andrew 
Scientific Advisor
Hegle, Andrew Peter
Director
Johnson, Matthew W.
Scientific Advisor
Kranzler, Henry R.
Member of Advisory Board
Maher, Nancy 
Special Advisor of Data Science & Regulatory Affairs
McKenna, Dennis 
Scientific Advisor
Timmermann, Christopher 
Scientific Advisor
Walker, Michael J. A.
Scientific Advisor


Primary Industry Classification
Biotechnology


Primary Office Location
999 West Broadway Suite 720 | Vancouver, BC | V5Z 1K5 | Canada
Phone: 604-562-3932   

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.02
Market Cap (mm)
1.2
Open
 0.02
Shares Out. (mm)
59.1
Previous Close
 0.02
Float %
97.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.02/ 0.02
Diluted EPS Excl. Extra Items
0.0051
52 wk High/Low
 0.05/ 0.02
P/Diluted EPS Before Extra
3.94x
Volume (mm)
0.0020
Avg 3M Dly Vlm (mm)
0.05
Beta 5Y
0.99


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:ENBI - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
HaluGen Life Sciences Inc.
HaluGen Life Sciences Inc. operates an online psychedelics pre-screening platform that identifies the inter-individual variations to psychedelic drug effects, highlights the short- and long-term genetic risk profiles, and categorizes the personal and familial risks. The company was founded in 2020 and is based in Vancouver, Canada. As of January 14, 2021, HaluGen Life Sciences Inc. operates as a subsidiary of Entheon Biomedical Corp.

United States and Canada
Health Care Technology
-
-
-
MPV Exploration Inc.
As of November 5, 2020, MPV Exploration Inc. was acquired by Entheon Biomedical Corp., in a reverse merger transaction. MPV Exploration Inc. engages in acquiring and exploring mineral resource properties in Canada. The company explores for copper, zinc, and silver deposits. It holds interests in the Umex Block West property comprising 14 cells covering an area of 777.63 hectares; and the Umex Block East property consisting of 111 cells covering an area of 6,163.28 hectares located to the west of the Town of Chapais, Québec. The company was formerly known as M.P.V. Explorations Inc. and changed its name to MPV Exploration Inc. in October 2018. MPV Exploration Inc. was incorporated in 2010 and is headquartered in Montreal, Canada.

United States and Canada
Diversified Metals and Mining
-
1.00
0.00
13089363 Canada Inc.
13089363 Canada Inc. was incorporated in 2021 and is based in Vancouver, Canada. 13089363 Canada Inc. operates as a subsidiary of Entheon Biomedical Corp.

United States and Canada
-
-
-
-
Heading Health Inc.
Heading Health Inc. owns and operates a chain of psychiatric clinics. It offers spravato; intramuscular (IM) ketamine; transcranial magnetic stimulation (TMS); telepsychiatry for depression, anxiety, PTSD, and OCD; and future psychedelic therapies treatments. Heading Health Inc. was incorporated in 2020 and is based in Austin, Texas with an additional center in Trophy Club, Texas.

United States and Canada
Health Care Facilities
6.00
-
-
Wonder Scientific Inc.
Wonder Scientific Inc. develops, manufactures, markets, and sells active pharmaceutical ingredients and nutrients for fungi and plants. The company’s products are used in global clinical and commercial demand for psychedelics treatment. The company was founded in 2020 and is based in Toronto, Canada.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-05-2022
Cancelled
Private Placement
Target
Entheon Biomedical Corp. (CNSX:ENBI)


2.39
Jan-14-2022
-
Shelf Registration
Target
Entheon Biomedical Corp. (CNSX:ENBI)


58.63
Jul-29-2021
-
Shelf Registration
Target
Entheon Biomedical Corp. (CNSX:ENBI)


0.00
Jan-14-2021
Jan-14-2021
Merger/Acquisition
Buyer
HaluGen Life Sciences Inc.
Entheon Biomedical Corp. (CNSX:ENBI)

3.31
Jan-04-2021
Jun-29-2023
Private Placement
Buyer
Heading Health Inc.
Entheon Biomedical Corp. (CNSX:ENBI),One Mind Accelerator,Gron Ventures, LLC,JAM Fund, LLC,Thiel Capital,Mystic Ventures,Anti Fund Investment Fund, LLC,Gaingels, LLC (nka:Gaingels Management, LLC)

4.50
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-31-2023
Executive/Board Changes - Other
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer
Jun-29-2023
Private Placements
Heading Health Inc. announced that it has received $4.5 million in funding from a group of investors
Apr-28-2023
Client Announcements
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin
Apr-19-2023
Annual General Meeting
Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023
Apr-19-2023
Shareholder/Analyst Calls
Entheon Biomedical Corp. - Shareholder/Analyst Call


Advisors
Most Recent Auditor
Manning Elliott LLP


Most Recent Auditor
Manning Elliott


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
ENBI
Flow of Funds Report for MPV Exploration Inc - prepared by Wright Investors Service
Notes
66


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Ko, Timothy 

1,000,001

1.69

0.0

Sep-13-2023


Gondi M.Sc., Ph.D., Christopher 

500,000

0.85

0.0

Oct-05-2022


Hegle Ph.D., Andrew Peter

100,000

0.17

0.0

Oct-05-2022



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Ko, Timothy 
1,000,001
(300,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Consulting Services, Dimethyltryptamine Delivery Systems (Future), Dimethyltryptamine Psychedelic Therapeutic Products (Future), Entheon ID (Future), Entheon IQ (Future), Entheon RX (Future), Licensing of DMT Delivery Systems (Future)


Upcoming Events
Date/Time
Type
Oct-27-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jul-31-2023
-
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
News Releases
121 KB
Jul-26-2023
-
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Interim Financial Statements
355 KB
Apr-28-2023
Feb-28-2023
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Interim Financial Statements
322 KB
Apr-28-2023
-
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
News Releases
125 KB
Apr-19-2023
Nov-30-2022
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Statement of Executive Compensation
188 KB
Mar-23-2023
Nov-30-2022
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Annual Financial Statements
340 KB
Mar-23-2023
Nov-30-2022
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Annual Financial Statements
299 KB
Mar-23-2023
Nov-30-2022
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Annual Financial Statements
568 KB
Mar-20-2023
-
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Notice of the Meeting and Record Date
164 KB
Mar-03-2023
-
Entheon Biomedical Corp. (CNSX:ENBI)
SEDAR
Material Change Report
160 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Ko, Timothy  (President, CEO & Director)
Sep-13-2023
Common shares
(300,000)
(305)
Private Disposition
(23.08)
Multiple
Jahns Pharm.D., Brian E. (Chief Business Officer)
Aug-04-2022
Common shares
(100,000)
(5,343)
Open Market Disposition
(100.00)
Multiple
Jahns Pharm.D., Brian E. (Chief Business Officer)
Jan-19-2022
Common shares
20,000
5,467
Open Market Acquisition
25.00
Multiple
Jahns Pharm.D., Brian E. (Chief Business Officer)
Jan-04-2022
Common shares
30,000
10,702
Open Market Acquisition
60.00
Multiple
Jahns Pharm.D., Brian E. (Chief Business Officer)
Jun-25-2021
Common shares
14,000
6,102
Open Market Acquisition
38.89
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Ko, Timothy 
President, CEO & Director
+1 (604) 562-3932
-
timothy@entheonbiomedical.com
Gondi, Christopher 
Independent Director
604-562-3932
-

Carhart-Harris, Robin L.
Scientific Advisor
604-562-3932
-

Erritzoe, David 
Scientific Advisor
604-562-3932
-

Greenshaw, Andrew 
Scientific Advisor
604-562-3932
-

Hegle, Andrew Peter
Director
604-562-3932
-

Johnson, Matthew W.
Scientific Advisor
604-562-3932
-

Kranzler, Henry R.
Member of Advisory Board
604-562-3932
-

Maher, Nancy 
Special Advisor of Data Science & Regulatory Affairs
604-562-3932
-

McKenna, Dennis 
Scientific Advisor
604-562-3932
-

Timmermann, Christopher 
Scientific Advisor
604-562-3932
-

Walker, Michael J. A.
Scientific Advisor
604-562-3932
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Ko, Timothy 
President, CEO & Director
+1 (604) 562-3932
-
timothy@entheonbiomedical.com
Kim, Soo-Whan 
Interim Chief Financial Officer
604-562-3932
-

Jahns, Brian E.
Chief Business Officer
604-562-3932
-

Pladson, Kelly 
Corporate Secretary
604-562-3932
-
kelly@niacorporateservices.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
